Cem CELİK, H Sebila DOKMETAS, Fatih KILICLI, Fettah ACIBUCU, Mustafa AYDEMİR

The effect of Vitamin D treatment on thyroid function and the levels of thyroid autoantibodies, TNF-?, IL-6, IL-1? in patients with autoimmune thyroiditis

Amaç: D vitamini tedavisinin otoimmun tiroid hastalığı ile ilişkisini araştırdık. Yöntem: Çalışmaya D vitamini yetersizliği ve beraberinde yeni tanı alan Hashimoto tiroiditi olan (HT) 54 hasta alındı. Hastalara 3 ay süreyle ayda bir 300.000 IU kolekalsiferol intramuskuler olarak verildi. Tanı esnasında ve D vitamini tedavisi sonrasında serbest T3(FT3), serbest T4 (FT4), tiroid stimulan hormon (TSH), anti tiroid peroksidaz (TPO) ve anti tiroglobulin (TG), 25(OH)D3, parathormon (PTH), kalsiyum (Ca), fosfor (P) ve alkalen fosfataz (ALP) seviyeleri ve yalnız 43 hastada TNF- ?, IL-6, IL-1b seviyeleri ölçüldü. Bulgular: Tedavi öncesi ve sonrası FT4, TSH, antiTPO, antiTG, PTH ve ALP seviyeleri açısından arada istatistiksel olarak anlamlı fark vardı (p

Otoimmun tiroiditi bulunan hastalarda D vitamini tedavisinin tiroid fonksiyonları ve tiroid otoantikorları, TNF-?, IL-6, IL-1? düzeyleri üzerine etkisi

Objective: To investigate the relationship between autoimmune thyroid disease and vitamin D treatment. Method: Fifty four (54) patients with both vitamin D deficiency and newly diagnosed euthyroid Hashimoto's thyroiditis (HT) were recruited for this study. The patients were given intramuscular administration of cholecalciferol at a dose of 300,000 IU/month for 3 months. At the time of diagnoses and after the treatment of vitamin D, free T3 (FT3), free T4 (FT4), thyroid stimulating hormone (TSH), antithyroid peroxidase (anti-TPO), antithyroglobulin (anti-TG), 25 (OH) D3, parathormone (PTH), calcium (Ca), phosphorus (P) and alkaline phosphatase (ALP) levels were measured in all patients; TNF-a, IL-6 and IL-1ß levels were measured in only 43 patients. Results: A statistically significant difference (p?0.05) was observed between the pre and post treatment FT4, TSH, antiTPO, antiTG, PTH and ALP levels. After the treatment of vitamin D, a statistically significant increase was found in 25 (OH) D3 and FT4 levels, and a significant decrease was found in TSH, antiTPO, antiTG, PTH and ALP levels, whereas no significant difference was noted in FT3, Ca, P, TNF- a, IL-6 and IL-1ß levels. Further, levels of vitamin D were not correlated with FT3, FT4, TSH, antiTPO, antiTG, TNF-a, IL-6 and IL-1ß levels (p?0.05). Conclusions: For patients with both vitamin D deficiency and newly diagnosed HT, treatment of vitamin D had a positive effect on the thyroid antigenicity and thyroid function.

PDF

___

1. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002; 87: 489- 99
2. Zaletel K. Determinants of thyroid autoantibody production in Hashimoto's thyroiditis. Expert Rev Clin Immunol 2007; 3: 217-23
3. McLachlan SM., Rapoport B. Why measure thyroglobulin autoantibodies rather than thyroid peroxidase autoantibodies? Thyroid 2004; 14: 510-20.
4. Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Clark F et al. The incidence of thyroid disorders in the community: a twentyyear follow-up of the Whickham Survey. Clin Endocrinol 1995; 43: 55- 68.
5. Tamer G, Arik S, Tamer I, Coksert D. Relative vitamin D insufficiency in Hashimoto's thyroiditis. Thyroid 2011; 21: 891-6.
6. Toubi E, Shoenfeld Y. The role of vitamin D in regulating immune responses. Isr Med Assoc J 2010; 12: 174-5.
7. Zipitis CS, Akobeng AK. Vitamin D supplementation in early childhood and risk of type 1 diabetes: a systematic review and meta-analysis. Arch Dis Child 2008; 93: 512-7.
8. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25- hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006; 296: 2832-8.
9. Hypponen E, Laara E, Reunanen A, Jarvelin MR, Virtanen SM. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001; 358: 1500-3.
10. Andjelkovic Z, Vojinovic J, Pejnovic N, Popovic M, Dujic A, Mitrovic D et al. Disease modifying and immunomodulatory effects of high dose 1 alpha (OH) D3 in rheumatoid arthritis patients. Clin Exp Rheumatol 1999; 17: 453-6.
11. Gaal J, Lakos G, Szodoray P, Kiss J, Horvath I, Horkay E et al. Immunological and clinical effects of alphacalcidol in patients with psoriatic arthropathy: results of an open, follow-up pilot study. Acta Derm Venereol 2009; 89: 140-4.
12. Goldberg P, Fleming MC, Picard EH. Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D. Med Hypotheses 1986; 21: 193- 200.
13. Arnson Y, Amital H, Shoenfeld Y. Vitamin D and auto-immunity: new aetiological and therapeutic considerations. Ann Rheum Dis 2007; 66: 1137-42.
14. Cantorna MT, Mahon BD. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Biol Med 2004; 229: 1136-42.
15. Cantorna MT, Zhu Y, Froicu M, Wittke A. Vitamin D status, 1,25- dihydroxyvitamin D3, and the immune system. Am J Clin Nutr 2004; 80: 1717-20.
16. Cantorna MT. Vitamin D and autoimmunity: is vitamin D status an environmental factor affecting autoimmune disease prevalence? Proc Soc Exp Biol Med 2000; 223: 230-3.
17. Jackson IMD, Hennessey JV. Thyroiditis. In: Becker KL (ed) Principles and Practice of Endocrinology and Metabo-lism, 3rd edition. Lippincott Williams & Wilkins, Philadel-phia, 2001; 456-9.
18. Kivity S, Agmon-Levin N, Zisappl M, Shapira Y, Nagy EV, Danko K et al. Vitamin D and autoimmune thyroid diseases. Cell Mol Immunol 2011; 8: 243-7.
19. Effraimidis G, Badenhoop K, Tijssen JG, Wiersinga WM. Vitamin D deficiency is not associated with early stages of thyroid autoimmunity. Eur J Endocrinol 2012;.167: 43-8.
20. Goswami R, Marwaha RK, Gupta N, Tandon N, Sreenivas V, Tomar N et al. Prevalence of vitamin D deficiency and its relationship with thyroid autoimmunity in Asian Indians: a community-based survey. Br J Nutr. 2009; 102: 382-6.
21. Bretz JD, Rymaszewski M, Arscott PL, Myc A, Ain KB, Thompson NW et al. TRAIL death pathway expression and induction in thyroid follicular cells. J Biol Chem 1999; 274: 23627-32.
22. Bretz JD, Baker Jr JR. Apoptosis and autoimmune thyroid disease: following a TRAIL to thyroid destruction? Clin Endocrinol 2001; 55: 1-11.
23. Zaletel K, Gaber??ek S. Hashimoto's Thyroiditis: From Genes to the Disease. Curr Genomics 2011; 12: 576-88.
24. Inoue N, Watanabe M, Nanba T, Wada M, Akamizu T, Iwatani Y. Involvement of functional polymorphisms in the TNFA gene in the pathogenesis of autoimmune thyroid diseases and production of anti-thyrotropin receptor antibody. Clin Exp Immunol 2009; 156: 199- 204.
25. Karanikas G, Schuetz M, Wahl K, Paul M, Kontur S, Pietschmann P et al. Relation of anti-TPO autoantibody titer and T lymphocyte cytokine production patterns in Hashimoto's thyroiditis. Clin Endocrinol 2005; 63: 191-6.
26. Nielsen CH, Brix TH, Leslie RG, Hegedüs L. A role for autoantibodies in enhancement of proinflammatory cytokineresponses to a self-antigen, thyroid peroxidise. Clin Immunol 2009; 133: 118-27.
27. Papanas N, Papazoglou D, Papatheodorou K, Antonoglou C, Kotsiou S, Maltezos E. Thyroxine replacement dose in patients with Hashimoto disease: a potential role for interleukin-6. Cytokine 2006; 35: 166-70.
28. Guillot X, Semerano L, SaidenbergKermanac'h N, Falgarone G, Boissier MC. Vitamin D and inflammation. Joint Bone Spine 2010; 77: 552-7.